A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China

Inclusion Criteria: \- Participant scheduled to receive at least one intravitreal OZURDEX® injection for DME as per most current local approved label after its approval for DME in China. Exclusion Criteria: * Concurrent participation in interventional clinical research that required treatment or use of an investigational agent. * Participants for whom OZURDEX® is contraindicated: * Participants with known hypersensitivity to OZURDEX® or any components of this product. * Participants with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. * Participants with late stage glaucoma that cannot be controlled with medication alone. * Aphakia with ruptured posterior lens capsule. * Eyes with anterior chamber intraocular lenses (ACIOL), iris- or scleral-fixated intraocular lenses, and ruptured posterior lens capsule.